• Median Technologies highlighted FDA 510(k) clearance for eyonis LCS, with CE marking still pending.
• Outlined U.S. commercial launch plans for eyonis LCS, supported by existing CPT III codes 0721T and 0722T with $650 hospital outpatient payment.
• Flagged a non-exclusive distribution agreement with Tempus covering the U.S. and Europe to support deployment through enterprise radiology workflows.
• Reported 2025 revenue of € 23.4 million, with the iCRO segment described as cash flow positive.
• Detailed an oversubscribed € 50 million capital increase, extending cash runway through H1 2028; 12.3 million warrants could add € 44.1 million through Jan. 31, 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Median Technologies SA published the original content used to generate this news brief on June 25, 2026, and is solely responsible for the information contained therein.